Literature DB >> 28724579

Novel Bivalent Viral-Vectored Vaccines Induce Potent Humoral and Cellular Immune Responses Conferring Protection against Stringent Influenza A Virus Challenge.

Claire M Tully1, Senthil Chinnakannan2, Caitlin E Mullarkey3, Marta Ulaszewska1, Francesca Ferrara4, Nigel Temperton4, Sarah C Gilbert1, Teresa Lambe5.   

Abstract

Seasonal influenza viruses are a common cause of acute respiratory illness worldwide and generate a significant socioeconomic burden. Influenza viruses mutate rapidly, necessitating annual vaccine reformulation because traditional vaccines do not typically induce broad-spectrum immunity. In addition to seasonal infections, emerging pandemic influenza viruses present a continued threat to global public health. Pandemic influenza viruses have consistently higher attack rates and are typically associated with greater mortality compared with seasonal strains. Ongoing strategies to improve vaccine efficacy typically focus on providing broad-spectrum immunity; although B and T cells can mediate heterosubtypic responses, typical vaccine development will augment either humoral or cellular immunity. However, multipronged approaches that target several Ags may limit the generation of viral escape mutants. There are few vaccine platforms that can deliver multiple Ags and generate robust cellular and humoral immunity. In this article, we describe a novel vaccination strategy, tested preclinically in mice, for the delivery of novel bivalent viral-vectored vaccines. We show this strategy elicits potent T cell responses toward highly conserved internal Ags while simultaneously inducing high levels of Abs toward hemagglutinin. Importantly, these humoral responses generate long-lived plasma cells and generate Abs capable of neutralizing variant hemagglutinin-expressing pseudotyped lentiviruses. Significantly, these novel viral-vectored vaccines induce strong immune responses capable of conferring protection in a stringent influenza A virus challenge. Thus, this vaccination regimen induces lasting efficacy toward influenza. Importantly, the simultaneous delivery of dual Ags may alleviate the selective pressure that is thought to potentiate antigenic diversity in avian influenza viruses.
Copyright © 2017 by The American Association of Immunologists, Inc.

Entities:  

Year:  2017        PMID: 28724579     DOI: 10.4049/jimmunol.1600939

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

Review 1.  Extending the Breadth of Influenza Vaccines: Status and Prospects for a Universal Vaccine.

Authors:  Annette Fox; Kylie M Quinn; Kanta Subbarao
Journal:  Drugs       Date:  2018-09       Impact factor: 9.546

2.  Vaccination with viral vectors expressing NP, M1 and chimeric hemagglutinin induces broad protection against influenza virus challenge in mice.

Authors:  Guha Asthagiri Arunkumar; Meagan McMahon; Vincent Pavot; Mario Aramouni; Andriani Ioannou; Teresa Lambe; Sarah Gilbert; Florian Krammer
Journal:  Vaccine       Date:  2019-08-06       Impact factor: 3.641

3.  Heterologous Combination of ChAdOx1 and MVA Vectors Expressing Protein NS1 as Vaccination Strategy to Induce Durable and Cross-Protective CD8+ T Cell Immunity to Bluetongue Virus.

Authors:  Sergio Utrilla-Trigo; Luis Jiménez-Cabello; Ruymán Alonso-Ravelo; Eva Calvo-Pinilla; Alejandro Marín-López; Sandra Moreno; Gema Lorenzo; Julio Benavides; Sarah Gilbert; Aitor Nogales; Javier Ortego
Journal:  Vaccines (Basel)       Date:  2020-06-29

Review 4.  Adenoviral Vectors as Vaccines for Emerging Avian Influenza Viruses.

Authors:  Lucas J Kerstetter; Stephen Buckley; Carly M Bliss; Lynda Coughlan
Journal:  Front Immunol       Date:  2021-01-29       Impact factor: 7.561

5.  The Combined Expression of the Nonstructural Protein NS1 and the N-Terminal Half of NS2 (NS21-180) by ChAdOx1 and MVA Confers Protection against Clinical Disease in Sheep upon Bluetongue Virus Challenge.

Authors:  Sergio Utrilla-Trigo; Luis Jiménez-Cabello; Eva Calvo-Pinilla; Alejandro Marín-López; Gema Lorenzo; Pedro Sánchez-Cordón; Sandra Moreno; Julio Benavides; Sarah Gilbert; Aitor Nogales; Javier Ortego
Journal:  J Virol       Date:  2021-11-17       Impact factor: 5.103

Review 6.  Leveraging on the genomics and immunopathology of SARS-CoV-2 for vaccines development: prospects and challenges.

Authors:  Idris Nasir Abdullahi; Anthony Uchenna Emeribe; Hafeez Aderinsayo Adekola; Sharafudeen Dahiru Abubakar; Amos Dangana; Halima Ali Shuwa; Sunday Theophilus Nwoba; Jelili Olaide Mustapha; Muyideen Titilope Haruna; Kafayat Adepeju Olowookere; Olawale Sunday Animasaun; Charles Egede Ugwu; Solomon Oloche Onoja; Abdullahi Sani Gadama; Musa Mohammed; Isa Muhammad Daneji; Dele Ohinoyi Amadu; Peter Elisha Ghamba; Nkechi Blessing Onukegbe; Muhammad Sagir Shehu; Chiladi Isomah; Adamu Babayo; Abdurrahman El-Fulaty Ahmad
Journal:  Hum Vaccin Immunother       Date:  2020-09-16       Impact factor: 3.452

7.  Integrase Defective Lentiviral Vector as a Vaccine Platform for Delivering Influenza Antigens.

Authors:  Alessandra Gallinaro; Martina Borghi; Roberta Bona; Felicia Grasso; Laura Calzoletti; Laura Palladino; Serena Cecchetti; Maria Fenicia Vescio; Daniele Macchia; Valeria Morante; Andrea Canitano; Nigel Temperton; Maria Rita Castrucci; Mirella Salvatore; Zuleika Michelini; Andrea Cara; Donatella Negri
Journal:  Front Immunol       Date:  2018-02-05       Impact factor: 7.561

8.  The Design and Development of a Multi-HBV Antigen Encoded in Chimpanzee Adenoviral and Modified Vaccinia Ankara Viral Vectors; A Novel Therapeutic Vaccine Strategy against HBV.

Authors:  Senthil K Chinnakannan; Tamsin N Cargill; Timothy A Donnison; M Azim Ansari; Sarah Sebastian; Lian Ni Lee; Claire Hutchings; Paul Klenerman; Mala K Maini; Tom Evans; Eleanor Barnes
Journal:  Vaccines (Basel)       Date:  2020-04-14

Review 9.  Adaptive immunity to SARS-CoV-2.

Authors:  Daniel M Altmann
Journal:  Oxf Open Immunol       Date:  2020-07-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.